Navidea Biopharmaceuticals (NAVB) Competitors

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Do institutionals and insiders believe in SCPS or NAVB?

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is SCPS or NAVB more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Which has more volatility and risk, SCPS or NAVB?

Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

Does the media prefer SCPS or NAVB?

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Navidea Biopharmaceuticals	Neutral

Which has higher earnings and valuation, SCPS or NAVB?

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Navidea Biopharmaceuticals	$8.13K	1.23	-$15.18M	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.